Four-year drug survival of apremilast in patients with psoriasis.
Kaplan-Meier survival curves
adverse drug events
apremilast
psoriasis
treatment
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
24
01
2023
received:
10
11
2022
accepted:
20
02
2023
medline:
3
7
2023
pubmed:
21
3
2023
entrez:
20
3
2023
Statut:
ppublish
Résumé
This real-world study at a single academic center retrospectively examined the drug survival of apremilast for patients with psoriasis. Retrospective information was extracted from the medical records of patients with psoriasis treated with apremilast at the Department of Dermatology, Jichi Medical University Hospital, between March 1, 2017, and June 31, 2021. In total, 281 patients were included in this study. Of these patients, 22% had psoriatic arthritis and 57% had a history of prior systemic treatment, including biologics, before the initiation of apremilast. The 1-, 2-, 3-, and 4-year drug survival rates were 54%, 41%, 32%, and 30%, respectively. Cox regression analysis revealed that sex, duration of plaque psoriasis (<10 years vs ≥10 years), presence of psoriatic arthritis, involvement of scalp lesions, involvement of palmoplantar lesion, involvement of nail lesions, having cardiometabolic comorbidities, and a history of prior systemic treatment did not have any significant impact on drug survival. The most common reason for apremilast discontinuation was inadequate efficacy (27%), followed by adverse events (12%). Approximately 49% of the patients experienced one or more adverse events. Diarrhea was the most common adverse event (24%), followed by nausea (19%) and headache (11%).
Identifiants
pubmed: 36938674
doi: 10.1111/1346-8138.16766
doi:
Substances chimiques
apremilast
UP7QBP99PN
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
960-963Informations de copyright
© 2023 Japanese Dermatological Association.
Références
Saruwatari H. Real-world experiences of apremilast in clinics for Japanese patients with psoriasis. J Dermatol. 2019;46:1166-9.
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387-99.
Crowley J, Thaçi D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:3107.
Graier T, Weger W, Sator PG, Salmhofer W, Gruber B, Jonak C, et al. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: a registry analysis. JAAD Int. 2020;2:62-75.
Sotiriou E, Tsentemeidou A, Sideris N, Lallas A, Kougkas N, Ioannides D, et al. Apremilast survival and reasons for discontinuation in psoriasis: five-year experience from a Greek tertiary care Centre. Dermatol Pract Concept. 2022;12:e2022076.
Galache-Osuna C, Reyes-García S, Salgueiro E, Bordallo-Landa J, Lozano A, Vázquez-López F, et al. Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: a long-term experience. Dermatol Ther. 2022;35:e15583.
Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real-world setting. J Dermatol. 2019;46:615-7.
Lee EB, Amin M, Egeberg A, Wu JJ. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting. J Eur Acad Dermatol Venereol. 2018;32:e393-4.
Filippi F, Patrizi A, Iezzi L, Carpanese MA, Conti A, Lasagni C, et al. Use of Apremilast® in the psoriasis treatment: a real-life multicenter Italian experience. Ital J Dermatol Venerol. 2022;157:313-7.
Distel J, Cazzaniga S, Jafari SM, Emelianov V, Schlapbach C, Yawalkar N, et al. Long-term effectiveness and drug survival of apremilast in treating psoriasis: a real-world experience. Dermatology. 2022;238:267-75.
Zeb L, Mhaskar R, Lewis S, Patel NS, Sadhwani D, Patel N, et al. Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center. Dermatol Ther. 2021;34:e14826.
Koguchi-Yoshioka H, Watanabe R, Matsumura Y, Ishitsuka Y, Inoue S, Furuta J, et al. Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis. J Dermatol Sci. 2021;103:109-15.